Drug evaluation: tagatose in the treatment of type 2 diabetes and obesity

Curr Opin Investig Drugs. 2006 Oct;7(10):924-35.

Abstract

Spherix Inc (formerly Biospherics) is developing tagatose, an orally active lactose derivative for the potential treatment of obesity and type 2 diabetes. The compound is also under investigation for the potential treatment of anemia, hemophilia and medical problems related to infertility, birth weight and excessive maternal food intake. Phase I and II clinical trials have been completed.

Publication types

  • Review

MeSH terms

  • Animals
  • Anti-Obesity Agents / adverse effects
  • Anti-Obesity Agents / metabolism
  • Anti-Obesity Agents / pharmacokinetics
  • Anti-Obesity Agents / therapeutic use*
  • Anti-Obesity Agents / toxicity
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Contraindications
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Hexoses / adverse effects
  • Hexoses / metabolism
  • Hexoses / pharmacokinetics
  • Hexoses / therapeutic use*
  • Hexoses / toxicity
  • Humans
  • Hypoglycemic Agents / adverse effects
  • Hypoglycemic Agents / metabolism
  • Hypoglycemic Agents / pharmacokinetics
  • Hypoglycemic Agents / therapeutic use*
  • Hypoglycemic Agents / toxicity
  • Obesity / drug therapy*
  • Structure-Activity Relationship

Substances

  • Anti-Obesity Agents
  • Hexoses
  • Hypoglycemic Agents
  • tagatose